Indeed, a small peptide encoding the N-cadherin binding site in EC1, producing an HAV peptide which antagonises N-cadherin, is being trialed as a cancer chemotherapeutic,18 demonstrating that this approach has potential for clinical use. This evidence concerns the gene CDH2 and cancer.